Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04408014
  4. Details
NCT04408014 Clinical Trial

Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo

COVID Clinical Trial

Official title:
Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04408014
Other study ID # COVID-19-Epi-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2020
Est. completion date July 30, 2020

Study information
Verified date February 2024
Source Butantan Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo

Description:

This is a cross-sectional study to estimate the prevalence of antibodies against SARS-CoV-2 is different population subgroups in the State of São Paulo

Recruitment information / eligibility
Status Completed
Enrollment 18901
Est. completion date July 30, 2020
Est. primary completion date July 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 100 Years
Eligibility Inclusion Criteria: - All potential volunteers invited to participate in the study. Exclusion Criteria: - All potential eligible participants, but who do not show interest in participating in the study.

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Serological test
IgM and IgG for SARS-CoV-2
• Nasopharyngeal Swab
PCR for SARS-CoV-2
• Oropharyngeal Swab
PCR for SARS-CoV-2

Locations
Country Name City State
Brazil Avenida Vital Brasil 1500 Sao Paulo

Sponsors (1)
Lead Sponsor Collaborator
Butantan Institute

Country where clinical trial is conducted

Brazil, 

Outcome
Type Measure Description Time frame Safety issue
Primary Prevalence of antibodies against SARS-CoV-2 through serological testing IgM and IgG antibodies against SARS-CoV-2 1 month
Primary Frequency of participants with a positive RT-PCR test result for SARS-CoV-2 Positive RT-PCR test result for SARS-CoV-2 1 month
See also
  Status Clinical Trial Phase
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Active, not recruiting NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04425720 - Use of Remote Monitoring for COVID-19 Patient N/A
Completed NCT04419610 - RAS and Coagulopathy in COVID19 Early Phase 1
Completed NCT04546581 - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Not yet recruiting NCT04524156 - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2 N/A
Completed NCT04441710 - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Terminated NCT04614025 - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 Phase 2
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2